JAMES FRANCIS MOORE, JR
Pilots at Hanna Dr, Newark, DE
License number
Delaware A2909951
Issued Date
Sep 2015
Expiration Date
Sep 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
407 W Hanna Dr, Newark, DE 19702
Professional information
Crystalline Efavirenz
US Patent:
6673372, Jan 6, 2004
Filed:
Jun 10, 1999
Appl. No.:
09/329421
Inventors:
Lilian A. Radesca - Newark DE
Michael B. Maurin - Wilmington DE
Shelley R. Rabel - Landenberg PA
James R. Moore - Newark DE
Michael B. Maurin - Wilmington DE
Shelley R. Rabel - Landenberg PA
James R. Moore - Newark DE
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 914
US Classification:
424489, 424464
Abstract:
The potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are-designated Forms 1, 2, 3 and 4, and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).
Hydroxybenzoate Salts Of Metanicotine Compounds
US Patent:
2006012, Jun 8, 2006
Filed:
Nov 9, 2005
Appl. No.:
11/270753
Inventors:
Gary Dull - Lewisville NC, US
Julio Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James Moore - Newark DE, US
Julio Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James Moore - Newark DE, US
International Classification:
A61K 31/44, C07D 213/26
US Classification:
514357000, 546329000
Abstract:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
Hydroxybenzoate Salts Of Metanicotine Compounds
US Patent:
2014003, Feb 6, 2014
Filed:
Oct 3, 2013
Appl. No.:
14/044914
Inventors:
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
James R. Moore - Newark DE, US
Assignee:
Targacept, Inc. - Winston-Salem NC
International Classification:
C07D 213/65
US Classification:
514351
Abstract:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
Hydroxybenzoate Salts Of Metanicotine Compounds
US Patent:
7459469, Dec 2, 2008
Filed:
Nov 9, 2005
Appl. No.:
11/270018
Inventors:
Julio A. Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
Assignee:
Targacept, Inc. - Winston-Salem NC
International Classification:
A01N 43/40, A61K 31/44, C07D 211/72, C07D 211/84, C07D 213/62, C07D 213/78
US Classification:
514351, 546300
Abstract:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
Hydroxybenzoate Salts Of Metanicotine Compounds
US Patent:
8053451, Nov 8, 2011
Filed:
Nov 4, 2008
Appl. No.:
12/264288
Inventors:
Julio A. Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
Assignee:
Targacept, Inc. - Winston-Salem NC
International Classification:
C07D 213/62, C07D 213/78, A01N 43/40, A61K 31/44
US Classification:
514351, 546300
Abstract:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
Hydroxybenzoate Salts Of Metanicotine Compounds
US Patent:
2008024, Oct 9, 2008
Filed:
Jun 19, 2008
Appl. No.:
12/142471
Inventors:
Gary Maurice Dull - Lewisville NC, US
Julio A. Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
Julio A. Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
Assignee:
Targacept, Inc. - Winston-Salem NC
International Classification:
A61K 31/44, A61P 25/00, A61P 25/28, A61P 25/16
US Classification:
514357
Abstract:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.
Hydroxybenzoate Salts Of Metanicotine Compounds
US Patent:
8580826, Nov 12, 2013
Filed:
Oct 26, 2011
Appl. No.:
13/281716
Inventors:
Julio A. Munoz - Walnut Cove NC, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
John Genus - Winston-Salem NC, US
James R. Moore - Newark DE, US
Assignee:
Targacept, Inc. - Winston-Salem NC
International Classification:
A61K 31/44, A61P 25/28, A61P 25/00, C07D 213/65, C07D 213/36
US Classification:
514351, 514357, 546300
Abstract:
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.